Becton Dickinson & Co. (BDX) Issues FY13 Earnings Guidance
Becton Dickinson & Co. (NYSE:BDX) issued an update on its FY13 earnings guidance on Friday morning. The company provided earnings per share guidance of $5.72-5.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.75, American Banking News reports. The company issued revenue guidance of 3.5-4% calc to ~$7.977-8.016 billion, compared to the consensus revenue estimate of $8.00 billion.
Shares of Becton Dickinson & Co. (NYSE:BDX) opened at 102.87 on Friday. Becton Dickinson & Co. has a 1-year low of $74.18 and a 1-year high of $104.98. The stock’s 50-day moving average is $99.47 and its 200-day moving average is $97.91. The company has a market cap of $19.979 billion and a price-to-earnings ratio of 13.80.
Becton Dickinson & Co. (NYSE:BDX) last released its earnings data on Thursday, August 1st. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.10. The company had revenue of $2.05 billion for the quarter, compared to the consensus estimate of $2.05 million. During the same quarter in the prior year, the company posted $1.52 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. On average, analysts predict that Becton Dickinson & Co. will post $5.75 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Piper Jaffray Cos. upgraded shares of Becton Dickinson & Co. (NYSE:BDX) from a neutral rating to an overweight rating in a research note to investors on Wednesday. They now have a $117.00 price target on the stock, up previously from $91.00. On a related note, analysts at RBC Capital raised their price target on shares of Becton Dickinson & Co. (NYSE:BDX) from $97.00 to $103.00 in a research note to investors on Monday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Becton Dickinson & Co. (NYSE:BDX) from $96.00 to $109.00 in a research note to investors on Monday, August 5th.
Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. Becton Dickinson & Co. currently has a consensus rating of Hold and an average target price of $102.81.
Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.